Abstract:Artemisinin and its derivatives are prodrugs that require heme for activation. Heme-activated artemisinins are free radicals and promiscuously bind hundreds of parasite proteins. ‘Artemisinin resistance’, manifesting as a delayed parasite clearance time, is due to changes in parasite life-cycle progression and enhanced stress response pathways rather than the parasite becoming insensitive to artemisinin throughout its life cycle. Optimizing current ACTs holds the promise to overcome ‘artemisinin resistance’. Artemisinin and its derivatives, in combination with partner drugs, are currently the most effective treatments for malaria parasite infection. Even though artemisinin has been widely used for decades, its mechanism of action had remained controversial until recently. Artemisinin combination therapies (ACTs) have recently been found to be losing efficacy in Southeast Asia. This ‘artemisinin resistance’, defined by a delayed parasite clearance time, has been associated with several genetic mutations. As with any other drug resistance phenotype, resistance can best be understood based on its mechanism of action. Recently, it was demonstrated that artemisinin attacks multiple parasitic targets, suggesting that mutations in drug targets are unlikely to cause high-level artemisinin resistance. These findings will help us to better understand the mechanisms of artemisinin resistance and suggest protocol modifications that may improve the efficacy of ACTs. Artemisinin and its derivatives, in combination with partner drugs, are currently the most effective treatments for malaria parasite infection. Even though artemisinin has been widely used for decades, its mechanism of action had remained controversial until recently. Artemisinin combination therapies (ACTs) have recently been found to be losing efficacy in Southeast Asia. This ‘artemisinin resistance’, defined by a delayed parasite clearance time, has been associated with several genetic mutations. As with any other drug resistance phenotype, resistance can best be understood based on its mechanism of action. Recently, it was demonstrated that artemisinin attacks multiple parasitic targets, suggesting that mutations in drug targets are unlikely to cause high-level artemisinin resistance. These findings will help us to better understand the mechanisms of artemisinin resistance and suggest protocol modifications that may improve the efficacy of ACTs.

Reversing artemisinin resistance by leveraging thermo-responsive nanoplatform to downregulating GSH

Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment

Profiling the Antimalarial Mechanism of Artemisinin by Identifying Crucial Target Proteins

Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties

Antimalarial Mechanisms and Resistance Status of Artemisinin and Its Derivatives

Improved Anti-Malarial Parasite Efficacy with Heparin-Artemisinin Nanoemulsions

Dual-pharmacophore artezomibs hijack the <i>Plasmodium</i> eubiquitin-proteasome system to kill malaria parasites while overcoming drug resistance

Unpacking ‘artemisinin Resistance’

Dual-pharmacophore artezomibs hijack the Plasmodium ubiquitin-proteasome system to kill malaria parasites while overcoming drug resistance

Mechanisms of in vitro resistance to dihydroartemisinin in Plasmodium falciparum.

Enhanced cell stress response and protein degradation capacity underlie artemisinin resistance in Plasmodium falciparum

Discovery, mechanisms of action and combination therapy of artemisinin.

Ph-Dependent Reversibly Activatable Cell-Penetrating Peptides Improve the Antitumor Effect of Artemisinin-Loaded Liposomes.

A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria

Commercialized artemisinin derivatives combined with colistin protect against critical Gram-negative bacterial infection

GPX4 Inhibition Synergistically Boosts Mitochondria Targeting Nanoartemisinin-Induced Apoptosis/ferroptosis Combination Cancer Therapy.

Increased Tolerance to Artemisinin in Plasmodium Falciparum is Mediated by a Quiescence Mechanism.

Facilitated Drug Repurposing with Artemisinin-Derived PROTACs: Unveiling PCLAF as a Therapeutic Target

Dimeric Artesunate Glycerophosphocholine Conjugate Nano-Assemblies As Slow-Release Antimalarials to Overcome Kelch 13 Mutant Artemisinin Resistance

Advances in the research on the targets of anti-malaria actions of artemisinin

Development, characterization, and evaluation of withaferin-A and artesunate-loaded pH-responsive acetal-dextran polymeric nanoparticles for the management of malaria